Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. (CRVS) on April 9, 2025, reporting events occurring on April 8, 2025. The Company is a Delaware corporation with its principal executive offices in South San Francisco, CA, and its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors appointed Richard van den Broek as a new Class II director, effective April 8, 2025. His term expires at the 2027 annual meeting of stockholders. Mr. van den Broek was also appointed to the Audit Committee and the Nominating Committee.
Compensation and Governance Details
- Annual Retainer: $35,000 for Board service, earned quarterly and prorated for the current quarter.
- Committee Fees: Additional $10,000 annually for the Audit Committee and $4,000 annually for the Nominating Committee, earned quarterly and prorated.
- Equity Grant: Automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the 2016 Equity Incentive Award Plan.
- Future Awards: Eligible for subsequent equity awards per the non-employee director compensation program.
- Indemnification: Mr. van den Broek will enter into the Company's standard indemnification agreement for directors and executive officers.
Investor Verification Checklist
- Verify the full text of the non-employee director compensation program filed as Exhibit 10.12 to the Form 10-K (March 25, 2025).
- Review the standard indemnification agreement filed as Exhibit 10.6 to the Form 10-K (March 25, 2025).
- Confirm the vesting schedule and exercise terms for the 30,000 share stock option grant.
- Check for any potential conflicts of interest regarding Mr. van den Broek's appointment to the Audit Committee.